Cargando…
The Removal of HBV in Plasma by Extracorporeal Immunoadsorption from Plasma: A Potential Therapy of Hepatitis B Patients
OBJECTIVE: To establish a novel HBV specific immunoadsorbent for the removing of HBV particles. METHODS: The anti-HBsAg monoclonal antibody was immobilized on sepharose beads to produce a sepharose anti-HBs column. Then the immunoadsorbent was evaluated and characterized by scanning electron microsc...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323487/ https://www.ncbi.nlm.nih.gov/pubmed/30671444 http://dx.doi.org/10.1155/2018/1269063 |
Sumario: | OBJECTIVE: To establish a novel HBV specific immunoadsorbent for the removing of HBV particles. METHODS: The anti-HBsAg monoclonal antibody was immobilized on sepharose beads to produce a sepharose anti-HBs column. Then the immunoadsorbent was evaluated and characterized by scanning electron microscopy. In addition, time-dependent effects of the eradication capacity of anti-HBsAg functionalized sepharose beads against HBV were investigated. RESULTS: Proposed immunoadsorbents exhibited a favorable biocompatibility as well as specificity. With the optimized recycle time, the decontamination performance of HBV particles and quantity of HBsAg were assessed either by real-time quantitative PCR or ELISA, which showed that the immunoadsorbent could remove approximately 90% of the HBV and 90% of the HBsAg from human plasma samples. CONCLUSIONS: All these results indicated that the novel immunoadsorbent could effectively remove HBV particles and likely serve as a novel therapy option or at least supplementary for the treatment regimen of HBV. |
---|